Key takeaways
Krystexxa (pegloticase) and colchicine (Glopreba, Mitigare) are both used to manage gout, but they work in different ways and are used in different situations. Krystexxa is an enzyme given as an intravenous infusion every two weeks, specifically for chronic gout that hasn't responded to other treatments. It works by converting uric acid into a substance that can be easily removed from the body. On the other hand, colchicine is an oral medication available in tablets, capsules, and oral solution forms. It is used both to treat and prevent gout flares and also treats familial Mediterranean fever (FMF). While Krystexxa is only available as a brand-name medication, colchicine is available in generic forms, which can make it more affordable. Krystexxa requires administration by a healthcare provider due to the risk of serious allergic reactions, whereas colchicine can be taken at home but has many potential drug interactions and side effects, including the risk of blood problems and muscle toxicity. Additionally, Krystexxa is not suitable for people with glucose-6-phosphate dehydrogenas (G6PD) deficiency, while colchicine should be used cautiously in those with kidney or liver disease.
